155 related articles for article (PubMed ID: 34885067)
1. Deciphering Promoter Hypermethylation of Genes Encoding for RASSF/Hippo Pathway Reveals the Poor Prognostic Factor of RASSF2 Gene Silencing in Colon Cancers.
Riffet M; Eid Y; Faisant M; Fohlen A; Menahem B; Alves A; Dubois F; Levallet G; Bazille C
Cancers (Basel); 2021 Nov; 13(23):. PubMed ID: 34885067
[TBL] [Abstract][Full Text] [Related]
2. Promoter Hypermethylation of Genes Encoding for RASSF/Hippo Pathway Members Reveals Specific Alteration Pattern in Diffuse Gliomas.
Levallet G; Creveuil C; Bekaert L; Péres E; Planchard G; Lecot-Cotigny S; Guillamo JS; Emery E; Zalcman G; Lechapt-Zalcman E
J Mol Diagn; 2019 Jul; 21(4):695-704. PubMed ID: 31055025
[TBL] [Abstract][Full Text] [Related]
3. Promoter methylation status of Ras-association domain family members in pheochromocytoma.
Richter AM; Zimmermann T; Haag T; Walesch SK; Dammann RH
Front Endocrinol (Lausanne); 2015; 6():21. PubMed ID: 25750636
[TBL] [Abstract][Full Text] [Related]
4. Decreased expression and frequent promoter hypermethylation of RASSF2 and RASSF6 correlate with malignant progression and poor prognosis of gastric cardia adenocarcinoma.
Guo W; Dong Z; Guo Y; Shen S; Guo X; Kuang G; Yang Z
Mol Carcinog; 2016 Nov; 55(11):1655-1666. PubMed ID: 26456015
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic inactivation of the RAS-effector gene RASSF2 in lung cancers.
Kaira K; Sunaga N; Tomizawa Y; Yanagitani N; Ishizuka T; Saito R; Nakajima T; Mori M
Int J Oncol; 2007 Jul; 31(1):169-73. PubMed ID: 17549418
[TBL] [Abstract][Full Text] [Related]
6. Aberrant Promoter Hypermethylation of RASSF Family Members in Merkel Cell Carcinoma.
Richter AM; Haag T; Walesch S; Herrmann-Trost P; Marsch WC; Kutzner H; Helmbold P; Dammann RH
Cancers (Basel); 2013 Nov; 5(4):1566-76. PubMed ID: 24252868
[TBL] [Abstract][Full Text] [Related]
7. Frequent epigenetic inactivation of RASSF2 in thyroid cancer and functional consequences.
Schagdarsurengin U; Richter AM; Hornung J; Lange C; Steinmann K; Dammann RH
Mol Cancer; 2010 Sep; 9():264. PubMed ID: 20920251
[TBL] [Abstract][Full Text] [Related]
8. Tumor suppressor C-RASSF proteins.
Iwasa H; Hossain S; Hata Y
Cell Mol Life Sci; 2018 May; 75(10):1773-1787. PubMed ID: 29353317
[TBL] [Abstract][Full Text] [Related]
9. Aberrant hypermethylation of RASSF2 in tumors and peripheral blood DNA as a biomarker for malignant progression and poor prognosis of esophageal squamous cell carcinoma.
Guo W; Dong Z; Cui J; Guo Y; Shen S; Guo X; Kuang G
Clin Exp Metastasis; 2016 Jan; 33(1):73-85. PubMed ID: 26482475
[TBL] [Abstract][Full Text] [Related]
10. Down-regulation of LATS1 and LATS2 mRNA expression by promoter hypermethylation and its association with biologically aggressive phenotype in human breast cancers.
Takahashi Y; Miyoshi Y; Takahata C; Irahara N; Taguchi T; Tamaki Y; Noguchi S
Clin Cancer Res; 2005 Feb; 11(4):1380-5. PubMed ID: 15746036
[TBL] [Abstract][Full Text] [Related]
11. RASSF1A: Not a prototypical Ras effector.
Gordon M; Baksh S
Small GTPases; 2011 May; 2(3):148-157. PubMed ID: 21776416
[TBL] [Abstract][Full Text] [Related]
12. RASSF2 methylation is a strong prognostic marker in younger age patients with Ewing sarcoma.
Gharanei S; Brini AT; Vaiyapuri S; Alholle A; Dallol A; Arrigoni E; Kishida T; Hiruma T; Avigad S; Grimer R; Maher ER; Latif F
Epigenetics; 2013 Sep; 8(9):893-8. PubMed ID: 23887284
[TBL] [Abstract][Full Text] [Related]
13. RASSF6; the Putative Tumor Suppressor of the RASSF Family.
Iwasa H; Jiang X; Hata Y
Cancers (Basel); 2015 Dec; 7(4):2415-26. PubMed ID: 26690221
[TBL] [Abstract][Full Text] [Related]
14. Frequent hypermethylation of MST1 and MST2 in soft tissue sarcoma.
Seidel C; Schagdarsurengin U; Blümke K; Würl P; Pfeifer GP; Hauptmann S; Taubert H; Dammann R
Mol Carcinog; 2007 Oct; 46(10):865-71. PubMed ID: 17538946
[TBL] [Abstract][Full Text] [Related]
15. Hypermethylation of
Gu Y; Wang Y; Wang Y; Luo J; Wang X; Ma M; Hua W; Liu Y; Yu FX
Front Cell Dev Biol; 2020; 8():586581. PubMed ID: 33195240
[TBL] [Abstract][Full Text] [Related]
16. The Ras effector RASSF2 is a novel tumor-suppressor gene in human colorectal cancer.
Akino K; Toyota M; Suzuki H; Mita H; Sasaki Y; Ohe-Toyota M; Issa JP; Hinoda Y; Imai K; Tokino T
Gastroenterology; 2005 Jul; 129(1):156-69. PubMed ID: 16012945
[TBL] [Abstract][Full Text] [Related]
17. Prognostic importance of RASSF2 expression in patients with gastric cancer who had undergone radical gastrectomy.
Aydin D; Bilici A; Kayahan S; Yavuzer D; Basar M; Aliustaoglu M
Clin Transl Oncol; 2016 Jun; 18(6):608-16. PubMed ID: 26459248
[TBL] [Abstract][Full Text] [Related]
18. The RASSF gene family members RASSF5, RASSF6 and RASSF7 show frequent DNA methylation in neuroblastoma.
Djos A; Martinsson T; Kogner P; Carén H
Mol Cancer; 2012 Jun; 11():40. PubMed ID: 22695170
[TBL] [Abstract][Full Text] [Related]
19. Nore1 and RASSF1 regulation of cell proliferation and of the MST1/2 kinases.
Avruch J; Praskova M; Ortiz-Vega S; Liu M; Zhang XF
Methods Enzymol; 2006; 407():290-310. PubMed ID: 16757333
[TBL] [Abstract][Full Text] [Related]
20. CpG island promoter hypermethylation of a novel Ras-effector gene RASSF2A is an early event in colon carcinogenesis and correlates inversely with K-ras mutations.
Hesson LB; Wilson R; Morton D; Adams C; Walker M; Maher ER; Latif F
Oncogene; 2005 Jun; 24(24):3987-94. PubMed ID: 15806169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
